gip/glp 1-agonist tirzepatide GLP-1 use tripled among non-diabetics, reaching $5.8B in 2022 Bumps and humps in the

Behavior and nutrition services activate automatically with Wellness Plus

41,42 GLP-1R is expressed in the cardiovascular system, and its knockout has implications for cardiovascular function

If you don't have enough GLP-1, or if it doesn't work the way it should in your body, a GLP-1 agonist can act like GLP-1 and give your system a boost

As the debate about GLP-1 agonists rages on in the colossal shadow of the caveats and concerns, scientific research continues its relentless pursuit of innovation

doi: 10.1001/jamahealthforum.2024.5586, PMID: [DOI] [PMC free article] [PubMed] [Google Scholar] 171

Findings: WEIGHT LOSS IN ADOLESCENTS The STEP TEENS study detailed below evaluated the effects of Wegovy on weight loss in obese adolescents aged 12 - 17 years RCT STEP TEENS Study - Wegovy vs Placebo for Weight Loss in Obese Adolescents, NEJM (2022) [PubMed abstract] The STEP TEENS study enrolled 201 obese adolescents aged 12 - 17 years Main inclusion criteria Age 12 to 10% Baseline characteristics Average age 15.4 years Female sex - 62% Average weight - 238 lbs (108 kg) Average BMI - 37 Randomized treatment groups Group 1 (134 patients): Wegovy 2.4 mg once weekly Group 2 (67 patients): Placebo Before treatment, all patients underwent a 12-week run-in phase where they received lifestyle interventions Wegovy was started at 0.25 mg once weekly and titrated to 2.4 mg over 16 weeks Percentage change in BMI from baseline to week 68 Primary outcome: Results Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone Findings: Summary Wegovy caused impressive weight loss in the STEP TEENS study, and its effects were greater than other drugs approved for adolescent obesity (see Qsymia and Saxenda)